Bone Loss in Allogeneic Transplant Patients
نویسندگان
چکیده
منابع مشابه
Allogeneic bone marrow transplant in a child with thalassaemia.
Transfusion dependent thalassaemia is a significant problem in Sri Lanka. In a study published in 2000, it was estimated that there were approximately 2000 transfusion dependent beta thalassaemia and HbE patients in Sri Lanka and the expenditure on them accounted for approximately 5% of the recurrent health budget of the country [1]. This number has by and large remained static over the past de...
متن کاملFatal Fulminant Hepatic Failure from Adenovirus in Allogeneic Bone Marrow Transplant Patients
We report two cases of fatal hepatic failure in patients who received matched unrelated bone marrow transplantation. Both patients presented with high fevers, abnormal liver functions tests, and hypodense lesions in the liver by CT scan. Histologic examination of postmortem liver samples demonstrated extensive necrosis, and immunohistochemistry was positive for adenovirus.
متن کاملPancytopenia after allogeneic bone marrow transplant due to copper deficiency.
Pancytopenia occurring 1 year or later after allogeneic bone marrow transplantation typically prompts a primary consideration for relapse. We present the case of a 15-year old-girl who underwent transplantation for therapy-related myelodysplasia secondary to Ewing sarcoma treatment who developed pancytopenia with myelodysplasia 1 year after transplant due to copper deficiency. Copper deficiency...
متن کاملSclerodermatous GVHD after Allogeneic Bone Marrow Transplant: a Review
Chronic graft versus host disease (cGVHD) is the leading cause of non-relapse mortality after allogeneic hematopoietic bone marrow transplantation (HCT) for blood malignancy in patients who survive for more than two years. cGVHD can significantly affect quality of life and cause decreased mobility amongst other grave consequences such as end-organ damage, contributing to morbidity and mortality...
متن کاملPentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients.
A recent study published by Bianco et all has suggested that pentoxyifylline [3,7-dimethyl-1-(5-oxo-hexyl)-xanthine] reduces morbidity and mortality in patients undergoing bone marrow transplantation (BMT). When compared with a “good risk” control group, pentoxifylline recipients experienced less mucositis (3.7 v 18.7 days,P = .004), less hepaticvenocclusive disease (10% v 65%,P = .001), a lowe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2020
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2019.12.158